Skip to content

Depression research published in 2026

Page 37 of 37: studies 721 to 725 of 725, newest first. Back to the depression overview

Studies

A Randomized Controlled Trial of Psilocybin for the Treatment of Obsessive-Compulsive Disorder

Online Publication Service of Würzburg University (Würzburg University) 2026 Katja Ehrmann

Obsessive Compulsive Disorder (OCD) is a prevalent mental disorder, with a lifetime prevalence of 2-3%, characterized by intrusive thoughts (obsessions) and repetitive behaviors (compulsions). These thoughts and behaviors take up a significant amount of time, cause immense distress, and compromise the quality of life of those who suffer from OCD. In addition to psychological factors such as...

Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder.

Annals of Medicine and Surgery 2026 Sana Rasheed, Rida Arif, Ahmed Asad Raza et al. 1 citation

Psilocybin, a naturally occurring psychedelic compound, has received attention as a novel therapeutic option for major depressive disorder (MDD), particularly in cases where traditional treatments prove ineffective. The study aims to evaluate psilocybin's therapeutic potential by examining its efficacy, safety, and mechanisms of action as well as addressing the societal and regulatory...

Ketamine Combined With Psychotherapy as a Treatment for Resistant Depression in a Public European Hospital.

Brain and Behavior 2026 Filipa Alves Da Silva, Rita Avelar, Bernardo Peixoto et al.

Depression affects around 280 million people worldwide, and about 30% of patients have treatment-resistant depression. Ketamine has significant scientific evidence supporting its use as an antidepressant, making it a promising approach for treatment-resistant cases. Combining ketamine with psychotherapy may enhance therapeutic response and support longer-lasting cognitive and behavioral change....

DOI: 10.1002/brb3.71164 (opens in new tab) Full text (opens in new tab) Off‐label ketamine Psychedelic‐assisted therapy Psychotherapy Resistant depression +2

Effects of esketamine on postoperative pain, anxiety, depression, sleep, and inflammation in pregnancies undergoing cesarean section: A randomized controlled trial.

PLoS One 2026 Yijun Wang, Xiaolu Lin, Xiang Zou et al.

Postoperative pain is the most notable issue after cesarean section (CS). The contributing factors include hyperalgesia, anxiety, depression, sleep disorders, and inflammation. In this study, we explored the effects of esketamine on pain, hyperalgesia, depression, anxiety, sleep disorders, and inflammation after CS. This randomized, blinded, controlled trial enrolled single-term pregnant women...

Anhedonia nonresponse to short-term ketamine administration for treatment-resistant bipolar depression.

Therapeutic Advances in Psychopharmacology 2026 Zofia Kachlik, Wiesław Jerzy Cubała, Michał Walaszek et al.

Anhedonia is a key symptom of bipolar depression and a target of ketamine's rapid antidepressant effects. However, many patients with treatment-resistant bipolar depression (TRBD) do not respond. This study aimed to identify clinical and sociodemographic characteristics that are associated with nonresponse of anhedonia following short-term ketamine treatment in TRBD. A retrospective analysis...

DOI: 10.1177/20451253251412629 (opens in new tab) Full text (opens in new tab) Ketamine Anhedonia Psychopharmacology Treatment-resistant bipolar depression